Prosecution Insights
Last updated: April 19, 2026
Application No. 17/999,008

N-PHENYLAMINOCARBONYL PYRIDINO-, PYRIMIDINO AND BENZO-TROPANES AS MODULATORS OF GPR65

Final Rejection §102§112§DP
Filed
Nov 16, 2022
Examiner
MOORE, SUSANNA
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Pathios Therapeutics Limited
OA Round
2 (Final)
68%
Grant Probability
Favorable
3-4
OA Rounds
3y 0m
To Grant
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allow Rate
842 granted / 1237 resolved
+8.1% vs TC avg
Strong +32% interview lift
Without
With
+32.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
68 currently pending
Career history
1305
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
18.6%
-21.4% vs TC avg
§102
17.3%
-22.7% vs TC avg
§112
36.6%
-3.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1237 resolved cases

Office Action

§102 §112 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This is a Final Office Action. Election/Restrictions Applicant's election without traverse of Group (I) in the reply filed on September 2, 2025 is acknowledged. Group (I), drawn to compounds of formulas (If), (Ib) and (Ie), embraced by claims 1-5, 9, 10, 14-21, 23-26 and 28-30 was elected by Applicant. Applicant has not pointed to any errors in the Examiner’s analysis of the different inventions. The requirement is still deemed proper and is therefore made FINAL. Applicant elected without traverse the following species: PNG media_image1.png 213 221 media_image1.png Greyscale and indicated claims 1-5, 9, 10, 14-18, 30, 32, 46 and 47 read on said species. However, Group (I) is limited to claims 1-5, 9, 10, 14-21, 23-26, 28-30 and 47. The elected species was searched and not found but is rejected under a NSDP section. Thus, the search was expanded. Claims 1-5, 9, 10, 14-21, 23-26, 28-30, 32, 46 and 47 are pending and claims 1-5, 9, 10, 14-18, 30 and 47 are under examination. Claim 47 is a new claim. Claims 19-21, 23-26, 28 and 29 are withdrawn based on the species election and claims 32 and 46 are withdrawn based on the lack of unity. Specification The objection to the abstract of the disclosure is withdrawn based on the amendments. Claim Rejections - 35 USC § 112 The rejections of claims 17 and 18 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for the phrases, “in the form of a mixture” and “and enantiomers thereof, and mixtures of enantiomers thereof, including racemic mixtures, and pharmaceutically acceptable salts and solvates,” are withdrawn based on the amendments. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 3, 4, 9, 10 and 14-16 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Aurora Fine Chemicals (Registry number 1903848-39-4, May 5, 2016, downloaded on June 6, 2025 from the STNext search report). The species shown below is found in the chemical catalog of Aurora Fine Chemicals, see the search report PNG media_image2.png 430 910 media_image2.png Greyscale Thus, said claims are anticipated. Applicant traverses by outlining the difference based on the point of attachment of the fused ring A, see below: PNG media_image3.png 205 253 media_image3.png Greyscale PNG media_image4.png 179 135 media_image4.png Greyscale PNG media_image5.png 236 286 media_image5.png Greyscale . Claim 3 has been amended to states, “wherein the wavy line denotes attachment of ring A to the ring containing N and Y,” see page 7. However, this is not sufficient to overcome the rejection. The claim does indicate which wavy line is attached to the Y variable of formula (Ib). Therefore, the rejection is maintained. Double Patenting The rejection of claims 1-5, 9, 10, 14-18, 30 and 47 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 28-31 of copending Application No. 18699825 in view of Patani, et al. (Chem. Rev., 96, 1996, pp. 3147-3176) is withdrawn based on the cancellation of claims 28-31 in the copending application. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUSANNA MOORE whose telephone number is (571)272-9046. The examiner can normally be reached Monday - Friday, 10:00 am to 7:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached on 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUSANNA MOORE/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Nov 16, 2022
Application Filed
Sep 28, 2025
Non-Final Rejection — §102, §112, §DP
Dec 31, 2025
Response Filed
Mar 21, 2026
Final Rejection — §102, §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600717
TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS
2y 5m to grant Granted Apr 14, 2026
Patent 12583868
JAK INHIBITORS AND METHODS FOR SYNTHESIZING AND USING THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12570656
PURINE COMPOUNDS FOR TREATING DISORDERS
2y 5m to grant Granted Mar 10, 2026
Patent 12552810
CRYSTALLINE FORMS OF CFTR MODULATORS
2y 5m to grant Granted Feb 17, 2026
Patent 12552804
TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+32.2%)
3y 0m
Median Time to Grant
Moderate
PTA Risk
Based on 1237 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month